We read with interest the article by Lotem et al titled "Skin Toxic Effects of Polyethylene Glycol–Coated Liposomal Doxorubicin" in the ARCHIVES.1 We write to suggest that it may be possible to partially protect against the mucocutaneous toxicity of polyethylene glycol–coated liposomal doxorubicin hydrochloride (Doxil) in cancer-treated patients with the use of cytoprotective prostaglandins.
Perkins TE, Malkinson FD, Finnerud CW. Cytoprotection Against Doxorubicin Toxicity. Arch Dermatol. 2001;137(11):1528. doi: